BioVenture VoiCes with Chris Garabedian Episode 34: General Atlantic's Brett Zbar
6 snips
Feb 9, 2026 
Brett Zbar, Managing Director and Head of Global Life Sciences at General Atlantic, is an experienced investor who built his career at Aisling and Foresite. He discusses differences between private equity and venture capital. He talks about GA’s patient capital and value-add model. He highlights thematic priorities like AI/ML, diagnostics, cardiometabolic and oncology, plus portfolio execution and board approach.
AI Snips
Chapters
Transcript
Episode notes
Spotting Megatrends And Leaning In With Conviction
- At Foresight Brett learned to spot megatrends early (GLP-1, AI) and to lean in with conviction when the risk/reward is right.
- Jim emphasized seeing around corners and taking calculated risks at the right time.
Homegrown Life Sciences Platform At GA With Top Support
- General Atlantic built an in-house life sciences platform to marry GA's growth equity strengths with life sciences' long timelines.
- Top leadership sponsorship (Bill Ford, Dave Hodgson) enabled patient capital, resources, and global reach.
Apply Firm Resources And Scale Capital Over Time
- Use the firm’s operating resources to accelerate portfolio companies: deploy patient capital, growth acceleration teams, human capital, and strategic marketing.
- GA typically writes $50–100M initial checks with line of sight to $200–300M core positions.